Active substances
Acetylsalicylic acid + Dipyridamole
- US FDA 12
- UK MHRA 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | BARR | Prescription | 14 Aug 2009 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | AMNEAL PHARMS | Prescription | 8 Mar 2016 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | SANDOZ | Prescription | 18 Jan 2017 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | PH HEALTH | Prescription | 18 Jan 2017 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | ZYDUS PHARMS | Prescription | 29 Aug 2017 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | DR REDDYS | Prescription | 10 Oct 2018 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | GLENMARK SPECLT | Prescription | 24 May 2019 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | MICRO LABS | Prescription | 11 Aug 2021 |
| AGGRENOX | 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule, extended release · oral | BOEHRINGER INGELHEIM | Discontinued | 22 Nov 1999 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | ANI PHARMS | Discontinued | 18 Jan 2017 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | SUN PHARM | Discontinued | 21 Aug 2018 |
| ASPIRIN AND DIPYRIDAMOLE | 25MG;200MG | capsule, extended release · oral | CHARTWELL MOLECULAR | Discontinued | 20 Mar 2019 |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| SVELUX 200MG/25MG MODIFIED RELEASE CAPSULES, HARD | PL 04416/1362 | SANDOZ LIMITED | POM |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.